In general, the findings suggest that targeting CXCR4 with Pep R enhances the effectiveness of colon cancer treatment by reducing stem-resistant cancer cell proliferation, reversing EMT-induced markers, and inhibiting cell growth. Here, CXCR4 is linked to colonic neoplasm.